Text Size

Ocular Treatments Targeting Separate Prostaglandin Receptors in Mice Exhibit Alterations in Intraocular Pressure and Optic Nerve Lipidome

Arcuri J, Elbaz A, Sharif NA, Bhattacharya SK


  • 2023
  • J Ocul Pharmacol Ther
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine at University of Miami, Miami, Florida, USA; Miami Integrative Metabolomics Research Center, Miami, Florida, USA; Molecular Cellular Pharmacology Graduate Program, University of Miami, Miami, Florida, USA; Eye-APC Duke-National University of Singapore Medical School, Singapore; Singapore Eye Research Institute, Singapore; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, Texas, USA; Department of Pharmacy Sciences, Creighton University, Omaha, Nebraska, USA; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA; Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom; Ophthalmology Innovation Center and Product Development Division, Santen Inc., Emeryville, California, USA

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022